Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis.
Saved in:
| Title: | Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis. |
|---|---|
| Authors: | Munoz J; Mayo Clinic, Phoenix, AZ. Electronic address: munoz.javier@mayo.edu., Rosenthal A; Mayo Clinic, Phoenix, AZ., Ip A; Hackensack Meridian School of Medicine, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ., Darrah JM; Cedars-Sinai Medical Center, Los Angeles, CA., Wang T; Genmab US Inc., Plainsboro, NJ., Zhang G; Genmab US Inc., Plainsboro, NJ., Mutebi A; Genmab US Inc., Plainsboro, NJ., Branchcomb T; Genmab US Inc., Plainsboro, NJ., Ding Z; Genmab US Inc., Plainsboro, NJ., Chhibber A; Genmab US Inc., Plainsboro, NJ., Navarro FR; Genmab, Copenhagen, Denmark., Risum M; Genmab, Copenhagen, Denmark., Atiya M; Genmab US Inc., Plainsboro, NJ., Brodkin S; Genmab US Inc., Plainsboro, NJ., Wang A; AbbVie, Inc., North Chicago, IL., Alshreef A; AbbVie, Inc., North Chicago, IL., Harb D; AbbVie, Inc., North Chicago, IL., Sacchi M; Genmab US Inc., Plainsboro, NJ., Hoehn D; Genmab US Inc., Plainsboro, NJ., Karimi YH; Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI. |
| Source: | Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2026 Feb; Vol. 26 (2), pp. e283-e291. Date of Electronic Publication: 2025 Oct 13. |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41206325 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Munoz+J%22">Munoz J</searchLink>; Mayo Clinic, Phoenix, AZ. Electronic address: munoz.javier@mayo.edu.<br /><searchLink fieldCode="AU" term="%22Rosenthal+A%22">Rosenthal A</searchLink>; Mayo Clinic, Phoenix, AZ.<br /><searchLink fieldCode="AU" term="%22Ip+A%22">Ip A</searchLink>; Hackensack Meridian School of Medicine, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ.<br /><searchLink fieldCode="AU" term="%22Darrah+JM%22">Darrah JM</searchLink>; Cedars-Sinai Medical Center, Los Angeles, CA.<br /><searchLink fieldCode="AU" term="%22Wang+T%22">Wang T</searchLink>; Genmab US Inc., Plainsboro, NJ.<br /><searchLink fieldCode="AU" term="%22Zhang+G%22">Zhang G</searchLink>; Genmab US Inc., Plainsboro, NJ.<br /><searchLink fieldCode="AU" term="%22Mutebi+A%22">Mutebi A</searchLink>; Genmab US Inc., Plainsboro, NJ.<br /><searchLink fieldCode="AU" term="%22Branchcomb+T%22">Branchcomb T</searchLink>; Genmab US Inc., Plainsboro, NJ.<br /><searchLink fieldCode="AU" term="%22Ding+Z%22">Ding Z</searchLink>; Genmab US Inc., Plainsboro, NJ.<br /><searchLink fieldCode="AU" term="%22Chhibber+A%22">Chhibber A</searchLink>; Genmab US Inc., Plainsboro, NJ.<br /><searchLink fieldCode="AU" term="%22Navarro+FR%22">Navarro FR</searchLink>; Genmab, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Risum+M%22">Risum M</searchLink>; Genmab, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Atiya+M%22">Atiya M</searchLink>; Genmab US Inc., Plainsboro, NJ.<br /><searchLink fieldCode="AU" term="%22Brodkin+S%22">Brodkin S</searchLink>; Genmab US Inc., Plainsboro, NJ.<br /><searchLink fieldCode="AU" term="%22Wang+A%22">Wang A</searchLink>; AbbVie, Inc., North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Alshreef+A%22">Alshreef A</searchLink>; AbbVie, Inc., North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Harb+D%22">Harb D</searchLink>; AbbVie, Inc., North Chicago, IL.<br /><searchLink fieldCode="AU" term="%22Sacchi+M%22">Sacchi M</searchLink>; Genmab US Inc., Plainsboro, NJ.<br /><searchLink fieldCode="AU" term="%22Hoehn+D%22">Hoehn D</searchLink>; Genmab US Inc., Plainsboro, NJ.<br /><searchLink fieldCode="AU" term="%22Karimi+YH%22">Karimi YH</searchLink>; Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101525386%22">Clinical lymphoma, myeloma & leukemia</searchLink> [Clin Lymphoma Myeloma Leuk] 2026 Feb; Vol. 26 (2), pp. e283-e291. <i>Date of Electronic Publication: </i>2025 Oct 13. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Comparative Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101525386 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2152-2669 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221522669%22">21522669 </searchLink><i>NLM ISO Abbreviation: </i>Clin Lymphoma Myeloma Leuk <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41206325 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.clml.2025.10.010 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: e283 Titles: – TitleFull: Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Munoz J – PersonEntity: Name: NameFull: Rosenthal A – PersonEntity: Name: NameFull: Ip A – PersonEntity: Name: NameFull: Darrah JM – PersonEntity: Name: NameFull: Wang T – PersonEntity: Name: NameFull: Zhang G – PersonEntity: Name: NameFull: Mutebi A – PersonEntity: Name: NameFull: Branchcomb T – PersonEntity: Name: NameFull: Ding Z – PersonEntity: Name: NameFull: Chhibber A – PersonEntity: Name: NameFull: Navarro FR – PersonEntity: Name: NameFull: Risum M – PersonEntity: Name: NameFull: Atiya M – PersonEntity: Name: NameFull: Brodkin S – PersonEntity: Name: NameFull: Wang A – PersonEntity: Name: NameFull: Alshreef A – PersonEntity: Name: NameFull: Harb D – PersonEntity: Name: NameFull: Sacchi M – PersonEntity: Name: NameFull: Hoehn D – PersonEntity: Name: NameFull: Karimi YH IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 02 Text: 2026 Feb Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 2152-2669 Numbering: – Type: volume Value: 26 – Type: issue Value: 2 Titles: – TitleFull: Clinical lymphoma, myeloma & leukemia Type: main |
| ResultId | 1 |
